Replay available

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.

Thu, August 6, 2026 at 8:30 AMendedReplay
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Melanie Herman

Head of Investor Relations

Todd Davis

Chief Executive Officer

Octavio Espinoza

Chief Financial Officer

Lauren Haig

Vice President, Portfolio Strategy and Investments

Matt Hewitt

Analyst at Craig-Hallum Capital Group

Annabelle Samimi

Analyst at Stifel

Yigal Nochomovitz

Analyst at Citigroup

Leland Gershel

Analyst at Oppenheimer & Co.

Joe Pantagenis

Analyst at H.C. Wainwright & Co.

Sahil Dhingra

Analyst at RBC Capital Markets

Replay transcript excerpt

Hello, everyone. Thank you for joining us and welcome to the Ligand Second Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Melanie Herman, Head of Investor Relations. Melanie, please go ahead. Good morning, everyone, and welcome to Ligand's second quarter 2026 earnings call. With me on the call today are CEO Todd Davis, Chief Financial Officer Octavio Espinoza, and Vice President of Portfolio Strategy and Investments, Lauren Haig. During the call today, we will review the financial results released earlier today and provide commentary on our partner portfolio and business development activity, followed by a question and answer session. Before we get started, I would like to point out we will be discussing non-GAAP results, which exclude certain items such as stock-based compensation, amortization of intangible assets, amortization or impairment of financial assets, and gains or losses from derivative assets, amongst others. I encourage you to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP measures which can be found in today's release available on our website. We believe these adjusted measures provide valuable insight into our core operating performance, both historically and moving forward. Our earnings release and a link to today's webcast can be found in the investor relations section of our website at ligand.com. This call is being recorded and the audio portion will be archived in the investor section of our website. On today's call, we will make forward-looking statements regarding our financial resul...

More from Ligand Pharmaceuticals Incorporated